Tikcro Technologies, Ltd.  

(Public, OTCMKTS:TIKRF)   Watch this stock  
Find more results for TIKRF
0.000 (0.00%)
Feb 23 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.25 - 0.64
Open     -
Vol / Avg. 0.00/743.00
Mkt cap 3.26M
P/E     -
Div/yield     -
EPS -0.12
Shares 9.88M
Beta -0.48
Inst. own 0%
Mar 29, 2017
Q4 2016 Tikcro Technologies Ltd Earnings Release (Estimated) Add to calendar

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -15.93% -9.99%
Return on average equity -16.45% -10.23%
Employees 2 -
CDP Score - -


Sapir Street 7 5th floor Kiryat Weizmann Science Park
NESS-ZIONA, 7403630
+972-8-9969800 (Phone)
+972-9-7442446 (Fax)

Website links


Tikcro Technologies Ltd. (Tikcro) provides funding for early-stage biotechnology projects with a focus on oncology. The Company provides funding for early-stage biotechnology projects originating in Israeli academic centers. The Company's product candidate antibodies focuses on blocking the ligand/receptor linkage of certain biological pathways, specifically antibodies that block anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed cell death protein 1 (PD-1), and by blocking these pathways to prevent the inhibition of patients' self immune system and its ability to attack cancerous cells. The Company focuses on antibody drug-candidates that block the binding surface domain and do not block adjacent domains. The Company's project focuses on the immune system pathways, which include CTLA-4 and its binding group of ligands; PD-1 and ligands PDL-1 and PDL-2, and T cell immunoreceptor with Ig and ITIM domains (TIGIT) and its binding group of ligands.

Officers and directors

Izhak Tamir Chairman of the Board
Age: 62
Aviv Boim Chief Executive Officer
Age: 47
Eric Paneth Director
Age: 64
Liat Simchayof Hadad External Director
Age: 28
Yiftach Atir Independent External Director
Age: 65